Westlake Village, CA – March 31, 2025 – NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition […]
Westlake Village, CA – March 27, 2025 – NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s clinical trial capabilities in India, facilitating the advancement of its development-stage neuro-oncology […]
Publication Date: March 27, 2025 Published By: Healthcare Executive Article Link: https://www.healthcareexecutive.in/blog/usc-licensed-startup On Wednesday, a USC-licensed startup biomedical company and Keck Medicine of USC neurosurgeon focused on treating brain cancer are taking their invention public along with India’s partnership for clinical trials. A USC-licensed startup that developed an intranasal drug delivery system for brain tumors […]
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market — Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a […]
— Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical biotechnology company, announced today that Dr. Victoria […]
— Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team — Westlake Village, CA – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced the appointment of Dr. Steven L. […]
— Delshad adds broad management and financial expertise to the NeOnc team — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed the Honorable Jimmy Delshad to its Board […]
— Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed Dr. Alan Chiang to its Board of Directors. Dr. […]
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://today.usc.edu/nasdaqs-opening-bell-will-ring-for-usc-research-startup/ A USC-licensed startup biomedical company and a Keck Medicine of USC neurosurgeon focused on treating brain cancer are taking their invention public. Such collaborations are an important way for researchers to bring promising treatments to patients. NeOnc founder Thomas Chen of Keck Medicine […]
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://healthcare360magazine.com/nasdaq-visionaries-neonc-technologies/ The landscape of healthcare is in a state of perpetual evolution, driven by relentless innovation and a desire to improve patient outcomes. As we move through 2025, the NASDAQ platform serves as a vital barometer for these advancements, showcasing the “Trailblazers in Healthcare […]
